TC BioPharm (TCBP) said Tuesday that it is planning to outsource various functions and switch to a "more decentralized" model, resulting in a workforce reduction of 20 employees.
The clinical-stage company said it plans to implement a contract development and manufacturing organization model for production and will consider options for new production sites using newly developed automated and other cell therapy production technologies, TC Biopharm said.
The company said it expects to complete the workforce reduction by the end of Q2 and to reduce the core operational burn rate by 55%, resulting in $2.1 million in partial 2025 savings and $4.2 million in annualized savings.
Shares of the company were up more than 3% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.